Oral KVD900 provides rapid inhibition of plasma kallikrein and fast improvement in attack symptoms in patients with hereditary angioedema

Smith, M.D., Duckworth, E.J., Hampton, S.L. et al. (3 more authors) (2022) Oral KVD900 provides rapid inhibition of plasma kallikrein and fast improvement in attack symptoms in patients with hereditary angioedema. In: Eastern Allergy Conference, 02-05 Jun 2022, Palm Beach, Florida.

Metadata

Item Type: Conference or Workshop Item
Authors/Creators:
  • Smith, M.D.
  • Duckworth, E.J.
  • Hampton, S.L.
  • Yea, C.M.
  • Audhya, P.
  • Feener, E.P.
Dates:
  • Published: 1 November 2022
  • Published (online): 1 November 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 07 Oct 2024 10:52
Last Modified: 07 Oct 2024 10:52
Published Version: https://www.ingentaconnect.com/contentone/ocean/aa...
Status: Published
Identification Number: 10.2500/aap.2022.43.220064
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics